Replies to post #124872 on Biotech Values

[jq1234]

It's interesting 150mg group was doing numerically better than 300mg group in reduction in both annual relapse rate and risk of sustained disability progression while 300mg group did do better numerically in secondary endpoint than 150mg group.

How many MS drugs BIIB can put on the market?